Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Senior Vice President, Innovative Sciences at Intellia Therapeutics
Tom Barnes has led platform-based research and drug discovery teams for over 20 years, and is responsible for extending the reach of Intellia’s CRISPR platform into new areas. A veteran entrepreneur who has helped launch several companies, he has turned creative scientific visions into successful businesses for both startups and established organizations. Tom has wide-ranging knowledge of biological systems through his work across diverse platforms, including genomics and gene discovery, small molecule drug repositioning, and protein engineering. Previously, as Vice President of Discovery at Eleven Biotherapeutics, Tom led his team in creating a novel chimeric cytokine antagonist, as well as two novel technologies. As Senior Vice President and site head of Gene Logic’s drug repositioning division, he oversaw technology platforms in metabolomics, toxicogenomics, gene expression informatics, and the genetics of drug metabolism and transport. Tom received his Ph.D. from the University of Cambridge, and completed research fellowships at Harvard Medical School and McGill University.